PMID- 21091091
OWN - NLM
STAT- MEDLINE
DCOM- 20110614
LR  - 20220331
IS  - 1651-2065 (Electronic)
IS  - 0036-5599 (Linking)
VI  - 45
IP  - 2
DP  - 2011 Mar
TI  - Comparison of the sensitivity and specificity of urine cytology, urinary nuclear 
      matrix protein-22 and multitarget fluorescence in situ hybridization assay in the 
      detection of bladder cancer.
PG  - 113-21
LID - 10.3109/00365599.2010.533694 [doi]
AB  - OBJECTIVE: This study aimed to compare the sensitivity, specificity, positive 
      predictive value (PPV) and negative predictive value (NPV) of urine cytology, 
      BladderChek(R) nuclear matrix protein-22 (NMP22) and UroVysion fluorescence in 
      situ hybridization (FISH) tests in patients with newly diagnosed bladder cancer, 
      those with recurrent bladder cancer, and those with bladder cancer but in 
      remission during surveillance. MATERIAL AND METHODS: Voided urine samples 
      obtained from 178 patients with suspected or known bladder cancer about to 
      undergo diagnostic or surveillance cystoscopy and 25 control subjects without the 
      disease were divided into four and used for urine culture and cytology, NMP22 
      BladderChek and UroVysion FISH tests. The sensitivity, specificity, PPV and NPV 
      for each test were calculated. Comparison was made between the ability of each 
      test to detect bladder cancer in the three category of patients listed. RESULTS: 
      Of the 178 patients with bladder cancer, 43 were newly diagnosed, 58 had 
      recurrent disease and 77 were in remission. The sensitivity of each test in newly 
      diagnosed patients was: urine cytology 28%, NMP22 88% and FISH 80%; and in 
      patients with recurrent disease: urine cytology 33%, NMP22 57% and FISH 85%. The 
      mean specificity for urine cytology, NMP22 and FISH was 95%, 67% and 48%, 
      respectively. CONCLUSION: Of the tests used in the study for detection of bladder 
      cancer, NMP22 appeared to be most cost-effective and rapid, with relatively high 
      sensitivity and specificity in all categories of patients. The NMP22 test may be 
      considered a new gold standard for the assessment of patients with known or 
      suspected bladder cancer.
FAU - Kehinde, Elijah O
AU  - Kehinde EO
AD  - Division of Urology, Department of Surgery, Faculty of Medicine, Kuwait 
      University, Kuwait. ekehinde@hotmail.com
FAU - Al-Mulla, Fahd
AU  - Al-Mulla F
FAU - Kapila, Kusum
AU  - Kapila K
FAU - Anim, Jehoram T
AU  - Anim JT
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101122
PL  - England
TA  - Scand J Urol Nephrol
JT  - Scandinavian journal of urology and nephrology
JID - 0114501
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Nuclear Proteins)
RN  - 0 (nuclear matrix protein 22)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/urine
MH  - Biopsy
MH  - Case-Control Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Middle Aged
MH  - Nuclear Proteins/*urine
MH  - Predictive Value of Tests
MH  - Sensitivity and Specificity
MH  - Urinalysis/*methods
MH  - Urinary Bladder Neoplasms/*diagnosis/pathology/urine
MH  - Young Adult
EDAT- 2010/11/26 06:00
MHDA- 2011/06/15 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - 10.3109/00365599.2010.533694 [doi]
PST - ppublish
SO  - Scand J Urol Nephrol. 2011 Mar;45(2):113-21. doi: 10.3109/00365599.2010.533694. 
      Epub 2010 Nov 22.